Saudi Central Bank Has $2.93 Million Holdings in IDEXX Laboratories, Inc. $IDXX

Key Points

• Saudi Central Bank increased its IDEXX Laboratories stake by 88.7% in the second quarter, ending with 5,560 shares valued at approximately $2.93 million.
• Institutional ownership remains high at 87.84%, with several major funds—including Wellington Management and Bank of New York Mellon—also increasing or initiating positions.
• IDEXX exceeded quarterly earnings and revenue expectations, reporting $4.27 in EPS and $1.22 billion in revenue. Analysts maintain a “Moderate Buy” consensus with an average price target of $747, versus a recent share price of $535.38.

Saudi Central Bank raised its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 88.7% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,560 shares of the company's stock after acquiring an additional 2,613 shares during the period. Saudi Central Bank's holdings in IDEXX Laboratories were worth $2,927,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently made changes to their positions in IDXX. Elyxium Wealth LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $3,666,459,000. J. Stern & Co. LLP increased its holdings in shares of IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock worth $1,795,072,000 after buying an additional 2,642,200 shares in the last quarter. Northwestern Mutual Wealth Management Co. increased its holdings in shares of IDEXX Laboratories by 63,503.9% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company's stock worth $977,210,000 after buying an additional 1,442,174 shares in the last quarter. Bank of New York Mellon Corp bought a new position in shares of IDEXX Laboratories in the 2nd quarter valued at $628,223,000. Finally, Wellington Management Group LLP boosted its holdings in shares of IDEXX Laboratories by 318.1% during the 4th quarter. Wellington Management Group LLP now owns 779,214 shares of the company's stock valued at $527,162,000 after acquiring an additional 592,834 shares in the last quarter. Institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Stock Performance

Shares of IDXX stock opened at $535.38 on Tuesday. IDEXX Laboratories, Inc. has a 1-year low of $518.55 and a 1-year high of $769.98. The company has a current ratio of 1.17, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The stock has a market cap of $42.18 billion, a price-to-earnings ratio of 37.65, a PEG ratio of 2.86 and a beta of 1.54. The stock has a 50-day moving average of $558.25 and a 200-day moving average of $569.41.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating the consensus estimate of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The business had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same period in the prior year, the business posted $3.50 earnings per share. The firm's revenue was up 9.7% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on IDXX shares. Weiss Ratings lowered IDEXX Laboratories from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, August 27th. Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a research note on Sunday, July 12th. Barclays reduced their price target on IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a report on Tuesday, August 11th. Citigroup upped their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the company a "neutral" rating in a research note on Wednesday, August 5th. Finally, UBS Group lifted their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and an average target price of $747.00.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.